

Special Issue

Pharmacovigilance Challenges of COVID-19 Vaccine

Message from the Guest Editor

The COVID-19 pandemic challenged all healthcare systems, which had to find ways to treat the disease and prevent its spread. Pharmaceutical companies faced the challenge of developing new vaccines, and health authorities had to evaluate them and authorize their release to the market. Once the vaccines were distributed, each country had to decide how to distribute them, educate healthcare professionals on their administration, and establish a proactive surveillance system to detect any potential safety issues. The success of the vaccination campaign depended on the collaboration of the whole of society. This Special Issue aims to provide an overview of all aspects of the pharmacovigilance system that was put in place and is still in action, as well as future perspectives. We welcome original papers, reviews, and studies that deal with the pharmacovigilance system, safety signals, immunology mechanisms, medication errors, and the past and future challenges related to COVID-19 vaccination.

Guest Editor

Prof. Ugo Moretti

Section of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Deadline for manuscript submissions

closed (30 November 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/197127

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).